In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA (fampridine), along with related assets, from Acorda Therapeutics, Inc. This transaction, valued at USD 185 million in cash, was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code, […]
Quanterix, a biomarker detection firm powering scientific research and breakthrough diagnostics, has introduced LucentAD, a new test designed to aid in the evaluation of patients exhibiting cognitive symptoms indicative of early Alzheimer’s disease (AD). This test allows healthcare providers to quickly assess the likelihood of a patient exhibiting amyloid pathology, a significant marker of Alzheimer’s […]
Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for the treatment of depression and movement disorders. Under the terms of the deal, the two US pharma companies will jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), […]
US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs for the treatment of multiple sclerosis (MS) and other neurological disorders. Convelo Therapeutics, which is headquartered in Cleveraland, Ohio, is engaged in discovering a new class of drugs that regenerate the […]
Prevacus, a leading US biopharmaceutical company, has announced a strategic partnership with medical device company Blinktbi, utilizing their novel EyeStat device to measure brain function objectively during a Phase 1 clinical trial of a new concussion drug. This collaboration highlights a significant advancement in the treatment and understanding of mild traumatic brain injuries (mTBI) and […]